<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611647</url>
  </required_header>
  <id_info>
    <org_study_id>171759</org_study_id>
    <nct_id>NCT03611647</nct_id>
  </id_info>
  <brief_title>Correlating Probiotic Dietary Supplements During Pregnancy With Maternal Microbiome Profiles</brief_title>
  <official_title>Correlating Probiotic Dietary Supplements During Pregnancy With Maternal Microbiome Profiles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to compare the microbiome profiles of healthy&#xD;
      pregnant women, both before and after the introduction of a probiotic supplement into the&#xD;
      maternal diet. Specifically, the investigators are performing a pilot randomized&#xD;
      double-blinded placebo-controlled trial, comparing the microbiome profiles of 40 healthy&#xD;
      pregnant women randomized to receive an oral probiotic containing a mixture of Lactobacillus&#xD;
      and Bifidobacterium species (20 mothers) versus an oral placebo (20 mothers) during the&#xD;
      first/second trimester of pregnancy. For each mother, the investigators will collect&#xD;
      biospecimens from the vagina, rectum, and urine, both before intervention, and 4-6 weeks&#xD;
      after intervention. These biospecimens will be analyzed to obtain their microbiome profiles&#xD;
      using next-generation sequencing. The primary outcome of interest is the vaginal microbiome,&#xD;
      with secondary outcomes including the microbiomes of the rectum and urine. Additionally, the&#xD;
      investigators will collect clinical data from the mother's and infant's medical records to&#xD;
      correlate our findings with pregnancy and postnatal outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vaginal Microbiome, 16S rRNA</measure>
    <time_frame>Baseline, and 4-6 weeks after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Rectal Microbiome, 16S rRNA</measure>
    <time_frame>Baseline, and 4-6 weeks after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Microbiome, 16S rRNA</measure>
    <time_frame>Baseline, and 4-6 weeks after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, taken by mouth once daily for 4-6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients â‰¥ 18 years of age&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age 6 weeks and 0 days through gestational age 13 weeks and 6 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients &lt;18 years of age&#xD;
&#xD;
          -  Multiple gestations&#xD;
&#xD;
          -  Gestational age less than or equal to 5 weeks and 6 days&#xD;
&#xD;
          -  Gestational age greater than or equal to 14 weeks and 0 days&#xD;
&#xD;
          -  Institutionalization for psychiatric disorder, mental retardation, or criminal&#xD;
             activity&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Major medical complication of pregnancy, including but not limited to: Diabetes,&#xD;
             Chronic hypertension, Severe obesity with body mass index greater than or equal to 40&#xD;
             kg/m2&#xD;
&#xD;
          -  Major surgical complications of pregnancy, including but not limited to: History of&#xD;
             Bariatric surgery&#xD;
&#xD;
          -  Major obstetrical complication of pregnancy, including but not limited to: History of&#xD;
             spontaneous preterm birth&#xD;
&#xD;
          -  Known maternal or fetal chromosomal abnormality&#xD;
&#xD;
          -  Major fetal anomaly&#xD;
&#xD;
          -  Intrauterine fetal demise&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) or Hepatitis&#xD;
&#xD;
          -  Chronic immunosuppressive medications or steroids&#xD;
&#xD;
          -  Current use of probiotic supplementation&#xD;
&#xD;
          -  Active urinary or vaginal infection&#xD;
&#xD;
          -  Current use of antibiotics&#xD;
&#xD;
          -  Current use of vaginal medication (e.g. vaginal progesterone)&#xD;
&#xD;
          -  Cerclage in place&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD, La Jolla Clinic, 8910 Villa La Jolla Drive</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD, Hillcrest Clinic, Medical Offices South</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD, Sorrento Valley Clinic, Directors Place</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>April 9, 2019</last_update_submitted>
  <last_update_submitted_qc>April 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Louise Laurent, MD/PhD</investigator_full_name>
    <investigator_title>Director of Perinatal Research; Department of Obstetrics, Gynecology, and Reproductive Sciences; Division of Maternal-Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Probiotic</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 31, 2019</submitted>
    <returned>January 14, 2020</returned>
    <submitted>April 13, 2020</submitted>
    <returned>April 22, 2020</returned>
    <submitted>November 16, 2020</submitted>
    <returned>December 9, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

